Peptide therapy is sold as the frontier of longevity medicine. Legally, most of it sits somewhere much less glamorous: a grey zone that got a little narrower in 2025, then shifted again on a single day in July 2026 — in a way almost every article you will read about it gets wrong.
If you have bought a GLP-1 online in the last two years, you have almost certainly been offered peptides. They appear in the checkout flow as add-ons, in the same price grid as your semaglutide, with names like BPC-157, sermorelin, CJC-1295 and TB-500. The pitch is consistent: faster healing, more lean muscle, better sleep, slower ageing.
What is almost never explained is that these substances occupy a completely different regulatory category from the GLP-1 you came for. Semaglutide and tirzepatide are FDA-approved drugs with published trial data. Most of the peptides sold alongside them are not approved for anything, have little or no human efficacy evidence, and until very recently could not lawfully be compounded for human use at all.
What a peptide actually is
A peptide is simply a short chain of amino acids — the same building blocks that make up proteins, just fewer of them. The dividing line is arbitrary and conventional: chains under roughly 40 amino acids get called peptides, longer ones get called proteins. Insulin is a peptide. So is semaglutide. So is the growth-hormone-releasing hormone your own hypothalamus makes.
This matters because the word "peptide" does no work as a safety or efficacy signal. It tells you about molecular size, not about whether something has been tested, whether it works, or whether it is legal to sell. Semaglutide is a peptide with tens of thousands of patients in randomised trials behind it. BPC-157 is a peptide whose human evidence base is close to empty. The category contains both.
Where each peptide actually stands
Tap any peptide for its current regulatory position. Updated after the FDA advisory committee vote of 23–24 July 2026 — which was a recommendation, not a rule change.
This is a plain-language summary of a moving regulatory picture, not legal or medical advice. A committee recommendation does not make a substance lawful to compound. Check the current FDA position before acting.
What changed in July 2026 — and what did not
For several years, FDA treated the most popular wellness peptides as substances with safety concerns. In practice that meant licensed compounding pharmacies could not lawfully prepare them for human use. BPC-157, TB-500, MOTS-c, CJC-1295 and AOD-9604 all sat in that bucket, which is why reputable clinics stopped offering them and less reputable sellers moved to labelling vials "for research use only".
On 23 and 24 July 2026, FDA's Pharmacy Compounding Advisory Committee met to consider whether several of these substances should be added to the Section 503A Bulks List — the roster of ingredients pharmacies may lawfully compound with. The committee voted in favour of six: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. The BPC-157 vote was close, at eight in favour, six against and one abstention.
This distinction is being lost at speed. Within days of the vote, sites were describing these peptides as "FDA-cleared" and "back on the legal list". They are neither. If you are being sold one of the six today on the basis of the July 2026 vote, the seller is either confused about the process or relying on you to be.
It also cuts the other way. A lot of older content — including legal explainers written in late 2025 — still describes all six as flatly prohibited with no prospect of change. That was accurate when written and is now missing half the picture. The honest summary is that these substances are not currently permitted, and that an advisory committee has recommended they should be.
The evidence, peptide by peptide
Regulatory status and clinical evidence are separate questions. A substance can be lawful and useless, or genuinely promising and unlawful. Below is what the human evidence actually supports for the peptides most commonly sold to GLP-1 patients.
What each peptide has actually been shown to do in humans
Rated on published human evidence for the claim as marketed. A low rating does not mean a substance is dangerous — it means the claim being sold to you has not been demonstrated.
Effectively all of the supporting work is in rodents. There are no adequate published randomised human trials for the healing claims made in marketing. FDA's prior classification cited lack of human safety data among its concerns.
Preclinical work only for the repair claims. FDA previously flagged immunogenicity — the risk of provoking an immune response — as a specific concern.
This narrow claim holds up: sermorelin is a GHRH analogue and injection does raise circulating hGH. It was an approved product until 2006 and is still used diagnostically.
A different claim entirely, and the evidence is scarce. Some research suggests improvements in lean mass, insulin sensitivity, wellbeing and libido, but definitive anti-ageing evidence is lacking and the use remains controversial.
No adequate human efficacy trials for the body-composition claims. FDA classified CJC-1295 as a substance with safety concerns, and it was not among those recommended in July 2026.
FDA proposed against listing it, citing immunogenicity risk and insufficient safety data. Human weight-loss trials have not demonstrated the marketed effect.
Included for contrast. Semaglutide and tirzepatide have large randomised placebo-controlled trials with consistent, substantial results — which is precisely what the wellness peptides lack.
Ratings summarise the weight of published human evidence for the claim as marketed — not whether a substance is safe, and not a treatment recommendation. Tap a row for what the evidence consists of.
Why your GLP-1 provider is selling you these
Follow the economics. Compounded semaglutide has collapsed in price — from several hundred dollars a month to under a hundred at several providers. That is good for patients and brutal for margins. Peptides, NAD+ and sermorelin are not price-compared by shoppers, carry no branded reference price, and can be sold at whatever the market bears.
You can see this directly in the price grids. A provider charging $99 for compounded semaglutide will list sermorelin at $99 and NAD+ at $93 on the same page. The GLP-1 is the loss leader that acquires you; the longevity shelf is where the margin lives.
That is not automatically sinister — plenty of legitimate businesses run loss leaders. But it should change how you read the recommendation. When the same company that profits from the add-on is also the one telling you that you need it, and the add-on has no approval and little human evidence, the incentive and the advice are pointing the same direction for reasons that have nothing to do with your health.
How peptide add-ons are typically priced alongside GLP-1s on provider sites
| Product | Typical published price | Approval status | Human efficacy evidence |
|---|---|---|---|
| Compounded semaglutide | $99–$151/mo | Copy of an approved drug | Strong for the approved product |
| Compounded tirzepatide | $149–$240/mo | Copy of an approved drug | Strong for the approved product |
| Sermorelin | $99–$149/mo | Discontinued 2006; compounded | Raises hGH; anti-ageing unproven |
| NAD+ injection | $93–$186/mo | Not an approved drug | Insufficient |
| BPC-157 | Varies; often unlisted | Not permitted; recommended Jul 2026 | Preclinical only |
Scroll the table sideways to see every column.
The questions to ask before you buy any of it
- Is this specific molecule an FDA-approved drug, a permitted compounding ingredient, or neither? Ask for the answer in writing.
- Which pharmacy compounds it, and is it a 503A or 503B facility? A provider that will not name the pharmacy is telling you something.
- What human trial supports the benefit you are being promised — not the mechanism, the benefit?
- What happens to my money if I stop after one month? Look for auto-rebill terms specifically.
- Is the clinician recommending this the same entity that profits from selling it?
- What are the interactions with my current medications, including the GLP-1?
Where this leaves a reasonable buyer
If you are on a GLP-1 and want to spend additional money to improve your results, the evidence points somewhere unglamorous: protein intake, resistance training, and sleep. Those have better support for preserving lean mass than any peptide on any clinic's menu, and they are free.
If you are still interested in peptides specifically, the defensible version is narrow. Wait for FDA to act on the July 2026 recommendation rather than buying from a seller who has decided the vote was the finish line. Prefer a named 503A or 503B pharmacy over a "research use only" vial, which is a labelling dodge rather than a category of medicine. And treat any clinic that describes the current status as settled as unreliable on everything else too.